1-2 of 2
Francesco Landi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Giuseppe Gritti, Federico Lussana, Silvia Ferrari, Anna Maria Barbui, Francesco Landi, Giulia Quaresmini, Gianmaria Borleri, Muriel Paganessi, Chiara Pavoni, Elisa Gotti, Chiara Capelli, Josee Golay, Martino Introna, Alessandro Rambaldi
Journal: Blood
Blood (2022) 140 (Supplement 1): 10325–10326.
https://doi.org/10.1182/blood-2022-170120
Published: 2022
Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Antonio Russo, MD, Alessandro Pulsoni, MD, Simonetta Viviani, MD, Francesca Ricci, MD, Rita Mazza, MD, Massimo Magagnoli, MD, Lucia Morello, MD, Francesco Landi, MD, Anna Guidetti, MD, Michele Merli, MD, Marcello Rodari, MD, Alessandra Serrao, MD, Giorgia Annechini, MD, Andrea Nervini, MD, Laura Giordano, Luca Castagna, MD, Francesco Passamonti, MD, Arturo Chiti, MD, Paolo Corradini, MD, Armando Santoro, MD, Carmelo Carlo-Stella, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1655.
https://doi.org/10.1182/blood-2018-99-115313
Published: 2018